Buy Requip through the unique service that maximize your savings

ANESTHESIOLOGY
ACCESSORY PRODUCTS
Agents
Merit Pharmaceuticals, Pharmaceutical/Medical/Surgical Products, Los Angeles, CA
Regulators
Allied Healthcare Products, Inc., St. Louis, MO
Precision Medical, Inc., Northampton, PA
Responsive Respiratory Inc., St. Louis, MO
Topical
Cryopak Industries, St. Leonard, PQ Canada
Gebauer Company, Cleveland, OH
EQUIPMENT
Anesthesia Delivery Systems…

GlaxoSmithKline PLC has received two significant marketing approvals from the Food and Drug Administration. Requip has been cleared as a treatment for moderate-to-severe restless legs syndrome in adults. Boostrix has been given the O.K. as the first combination vaccine to help protect adolescents against whooping cough.

Related Results

Requip for RLSRequip reduces risk of dyskine…

A recently released study shows that early treatment with the Parkinson’s disease drug Requip significantly reduces the risk of dyskinesias, involuntary body movements that are often associated with levodopa, a popular Parkinson’s therapy. SmithKline Beecham PLC received Food and Drug Administration approval for Requip, a second-generation dopamine agonist, about two years ago.

…

SmithKline Beecham and SkyePharma have entered into a development and licensing agreement for a once-daily version of SKB’s anti-Parkinson’s disease drug, Requip (ropinirole), using SkyePharma’s Geomatrix oral deliv…

M2 PRESSWIRE-17 September 1999-SMITHKLINE BEECHAM: Smithkline Beecham and SkyePharma sign agreement to develop once daily Requip (C)1994-99 M2 COMMUNICATIONS LTD RDATE:150999 LONDON — SmithKline Beecham (SB) and SkyePharma PLC announced today that they have entered into a development and licensing agreement for a once-daily version of SB’s…

Requip XL (ropirinole extended release tablets) have been approved by the Food and Drug Administration for the treatment of the signs and symptoms of idiopathic Parkinson’s disease. It is the first and only oral once-daily non-ergot do…

M2 PRESSWIRE-30 July 1999-SMITHKLINE BEECHAM: New study shows early treatment with Parkinson’s drug Requip significantly reduces the risk of dyskinesias and is effective long-term (C)1994-99 M2 COMMUNICATIONS LTD RDATE:290799 Vancouver, Canada — Reports of Parkinson’s disease affecting public figures such as Janet Reno, Michael J.

Related Results

Requip for RLSRequip reduces risk of dyskinesiasRequip now has generic competitorsGSK’s Requip significantly imp…

SkyePharma - Update on Convertible Bonds and Current Trading

LONDON, UK, 8 July, 2008 - SkyePharma PLC (LSE: SKP) today provides an
update on progress with the convertible bonds and current trading.

Progress with convertible bon…

CHAPEL HILL, N.C., June 25 /PRNewswire/ — New research that explores the tactics and strategies that lead to successful product development, launch and management is now available in the Best Practice Database, an online research repository managed by research and consulti…

Most people who suffer from restless leg syndrome are tormented each night through this severe pain and leg motion. Drug companies want you to believe that they have a cure, but a simple look at the headlines will show what many restless leg sufferers are scared of:
Mirapex: “Patients taking certain medicines to treat Parkinson’s disease or RLS, including Mirapex… have reported problems wi…